Urinary Tract Infection Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and By Region, Competition
The Global Urinary Tract Infection Therapeutics Market, valued at USD 7.20 billion in 2022, is expected to exhibit substantial growth in the forecast period, with a projected CAGR of 3.12% through 2028. Urinary tract infection (UTI) therapeutics encompass a range of medical treatments and interventions employed to manage and treat infections occurring in the urinary tract. UTIs are bacterial infections that can affect various parts of the urinary system, including the bladder, urethra, ureters, and kidneys. The primary objectives of UTI therapeutics are to alleviate symptoms, eliminate infecting bacteria, and prevent complications. The most common and effective treatment for bacterial UTIs involves antibiotics, which function by targeting and eradicating the bacteria responsible for the infection. The selection of antibiotics is influenced by factors such as the type of bacteria, antibiotic susceptibility, and patient-specific considerations. Empiric therapy, which involves prescribing antibiotics based on common bacterial pathogens and resistance patterns in the patient's community, is a practical approach that offers rapid treatment while awaiting specific laboratory test results.
Key Market Drivers:
1. **Advancements in Diagnostics:** Ongoing advancements in diagnostic techniques for urinary tract infections (UTIs) have the potential to enhance patient outcomes by enabling more accurate and timely diagnoses, leading to precise and targeted treatment strategies. Rapid diagnostic tests, designed for point-of-care use, are being developed to provide quick results, empowering healthcare providers to make treatment decisions without waiting for laboratory results. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification assays can identify the genetic material of bacteria causing the infection, offering high sensitivity and specificity. Researchers are also exploring specific biomarkers present in urine or blood to differentiate between bacterial and non-bacterial causes of symptoms, aiding in treatment decisions. The development of smartphone apps and devices with integrated diagnostic capabilities allows users to perform simple urine tests at home and receive immediate results. Microfluidic platforms are being designed to automate and miniaturize diagnostic processes, enabling efficient analysis of urine samples for bacterial presence and biomarkers. Mass spectrometry-based techniques are being employed to identify bacterial pathogens and detect antimicrobial resistance, offering comprehensive insights into the infecting organisms. Advanced culture techniques, including automated systems, expedite the identification of bacterial species causing UTIs and provide information about antibiotic susceptibility. Imaging methods like ultrasound and computed tomography (CT) scans help visualize the urinary tract and identify structural abnormalities that may contribute to recurrent UTIs. Endoscopic procedures allow the direct visualization of the urinary tract, aiding in the identification of anatomical abnormalities, stones, or other factors influencing UTIs. Artificial intelligence (AI) and machine learning algorithms are applied to analyze extensive datasets, identifying patterns and predicting UTI outcomes based on patient history, symptoms, and test results. Metabolomics involves analyzing urine metabolites to gain insights into host-microbe interactions during UTIs, potentially leading to new diagnostic markers. Non-invasive methods for UTI diagnosis, such as urine odor analysis and sensor-based technologies for bacterial detection, are also under exploration. These advancements are expected to drive the growth of the Global Urinary Tract Infection Therapeutics Market.
2. **Growing Aging Population:** The aging population is more vulnerable to infections, including UTIs, due to a decline in immune system function. This vulnerability leads to a higher incidence of infections and a greater demand for appropriate treatment. Older adults often have underlying health conditions like diabetes, kidney disease, and urinary incontinence, which can increase the risk of UTIs and necessitate specialized therapeutics. Anatomical changes in the urinary tract, such as weakened bladder muscles and reduced bladder capacity, contribute to UTIs in older individuals, requiring tailored treatment approaches. The use of urinary catheters, common in older adults, raises the risk of catheter-associated UTIs, making effective therapeutics essential for their management. Additionally, older adults may be more prone to UTIs during hospital stays or in long-term care settings. Effective treatments are crucial in preventing complications and improving patient outcomes. The aging population often experiences polypharmacy, the use of multiple medications, which may increase the risk of UTIs or interact with antibiotics, necessitating careful consideration of therapeutics. Effective therapeutics play a vital role in preventing recurrent infections and associated complications. UTIs can significantly impact the quality of life for older adults, leading to discomfort, pain, and functional limitations. Access to effective therapeutics is essential to alleviate symptoms and enhance well-being. The aging population tends to have higher healthcare utilization rates, including diagnosis, treatment, and management of UTIs, contributing to the demand for UTI therapeutics. As people live longer, they have a higher cumulative risk of experiencing UTIs over their lifetimes. The sustained demand for UTI therapeutics is driven by the ongoing healthcare needs of the aging population, thereby accelerating the demand for the Global Urinary Tract Infection Therapeutics Market.
3. **Increasing Antibiotic Resistance Concerns:** Antibiotic resistance is a growing concern in healthcare as bacteria evolve to resist the effects of antibiotics, diminishing the effectiveness of traditional treatments. With rising antibiotic resistance, the range of antibiotics available for treating UTIs narrows, underscoring the need for novel therapeutic options. UTIs caused by antibiotic-resistant bacteria pose challenges as they are harder to treat with conventional antibiotics, leading to treatment failures, prolonged infections, and a heightened risk of complications. Additionally, antibiotic-resistant UTIs are more likely to recur, as bacteria surviving antibiotic treatment can result in relapses. Effective UTI therapeutics are essential for preventing recurrent infections and halting the cycle of resistance. In healthcare settings, patients with antibiotic-resistant UTIs may experience extended hospital stays, increased healthcare costs, and a higher risk of adverse outcomes. Effective therapeutics are crucial for managing and preventing these infections. The spread of resistant bacteria within communities amplifies the risk of acquiring antibiotic-resistant UTIs, emphasizing the urgency of developing and using effective therapies to mitigate proliferation. Antibiotic resistance is a global public health concern, and infections that were once easily treatable may become life-threatening due to the lack of effective antibiotics. The escalating healthcare costs associated with treating antibiotic-resistant infections, including UTIs, strain healthcare systems and burden both patients and societies. Effective therapeutics can help alleviate these economic challenges. Governments, healthcare organizations, and international bodies are actively addressing antibiotic resistance through awareness campaigns, surveillance programs, and research efforts, emphasizing the importance of developing effective UTI therapeutics. The urgency surrounding antibiotic resistance has spurred research into new drug classes, alternative treatments, and combination therapies. Pharmaceutical companies are investing in the development of innovative therapeutics to combat resistant UTIs. Healthcare providers are increasingly practicing antibiotic stewardship to promote responsible antibiotic use. Developing effective UTI therapeutics that are less likely to contribute to resistance aligns with these stewardship principles. The complexity of antibiotic resistance patterns necessitates personalized treatment strategies, addressing specific bacterial strains and resistance mechanisms. These factors are expected to expedite the demand for the Global Urinary Tract Infection Therapeutics Market.
Key Market Challenges
Emergence of Virulent Strains
Virulent strains of bacteria can exhibit higher levels of resistance to antibiotics, rendering conventional treatments less effective. This can lead to prolonged infections, increased healthcare utilization, and a higher risk of complications. Virulent strains often cause more severe infections with more pronounced symptoms. Patients infected with such strains may experience more discomfort and require more aggressive treatment strategies. UTIs caused by virulent strains can be associated with a higher risk of complications, including kidney infections (pyelonephritis) and bloodstream infections (bacteremia), which can be life-threatening if not promptly treated. Hospitals and healthcare settings can be reservoirs for virulent bacterial strains. UTIs acquired in healthcare settings often involve more resistant and virulent strains, necessitating specialized therapeutics and infection control measures. The emergence of drug-resistant and virulent strains can limit the available treatment options for UTIs. Healthcare providers may need to rely on more powerful antibiotics, combination therapies, or alternative treatment approaches. Treating infections caused by virulent strains can lead to longer hospital stays, increased healthcare costs, and the need for more intensive interventions. This places a burden on healthcare systems and patients alike. The emergence of new virulent strains underscores the need for ongoing antibiotic development. However, the process of developing and bringing new antibiotics to market can be complex and time-consuming.
Limited New Drug Development
The rise of antibiotic-resistant bacteria is a pressing concern. Limited new drug development contributes to a shortage of effective antibiotics against resistant strains, making it difficult to treat certain UTIs. The absence of new drugs can lead to treatment failures, prolonged infections, and recurrent UTIs. This can result in patient discomfort, increased healthcare utilization, and higher costs. With few new drugs entering the market, healthcare providers may have limited options to choose from. This could lead to over-reliance on a small set of antibiotics, potentially exacerbating resistance issues. The lack of new drug development can lead to economic consequences, including increased healthcare costs due to extended treatment periods and hospitalizations for severe cases. A lack of innovation hinders the discovery of novel treatment approaches, leaving patients with fewer alternatives to traditional antibiotics. The aging population and increased healthcare demand mean that UTI treatment requirements are on the rise. New drugs are crucial to meet this growing demand. Limited potential for profit from developing new UTI drugs might discourage pharmaceutical companies from investing in research and development efforts. UTIs can be caused by various bacterial species. Developing drugs that target a wide range of pathogens requires substantial research and resources.
Key Market Trends
Antibiotic Stewardship
Antibiotic stewardship refers to the coordinated efforts to promote the responsible and judicious use of antibiotics to prevent the development of antibiotic resistance, improve patient outcomes, and optimize healthcare resources. Antibiotic stewardship programs aim to ensure that antibiotics are prescribed only when necessary and appropriate. This approach helps prevent the overuse and misuse of antibiotics, preserving their effectiveness for future use. One of the primary goals of antibiotic stewardship is to combat the development of antibiotic resistance. By limiting unnecessary antibiotic use, the emergence and spread of resistant bacteria can be slowed down. Antibiotic stewardship encourages healthcare providers to explore alternative treatment options, such as non-antibiotic therapies, for managing UTIs when appropriate. Stewardship practices emphasize individualized treatment plans based on the patient's condition, the causative pathogen, and antibiotic susceptibility. This approach improves treatment outcomes and minimizes unnecessary exposure to antibiotics. Antibiotic stewardship programs involve educating healthcare professionals, patients, and the public about the importance of proper antibiotic use, the risks of resistance, and the benefits of responsible prescribing. Stewardship aligns with evidence-based guidelines for UTI treatment, ensuring that antibiotics are prescribed according to established best practices. Electronic health record systems and clinical decision support tools can assist healthcare providers in selecting appropriate antibiotics based on patient-specific factors and local resistance patterns.
Segmental Insights
Indication Insights
In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by complicated UTI segment in the forecast period and is predicted to continue expanding over the coming years. Complicated UTIs are infections that occur in individuals with anatomical or functional abnormalities of the urinary tract, underlying health conditions, or compromised immune systems. These infections tend to be more severe and challenging to treat. Therefore, healthcare providers may rely on more potent or specialized therapies, contributing to the dominance of this segment. The complexity of complicated UTIs might necessitate the use of specialized or combination therapies to effectively treat the infection. This requirement for tailored treatments could result in a higher demand for specific therapeutic options. As the population ages and chronic health conditions become more prevalent, the incidence of complicated UTIs could increase. This demographic shift might contribute to the dominance of this segment.
Drug Insights
In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by quinolones drugs segment and is predicted to continue expanding over the coming years. Quinolones are broad-spectrum antibiotics, which means they are effective against a wide range of bacteria. UTIs can be caused by various bacterial strains, and quinolones' ability to target a broad spectrum of bacteria makes them versatile in treating different types of UTIs. Many quinolone antibiotics can be administered orally, making them convenient for both healthcare providers and patients. This ease of administration can contribute to their popularity in the treatment of UTIs. Quinolones often have a relatively fast onset of action, leading to quick symptom relief for patients suffering from UTIs. Healthcare providers often have experience with prescribing quinolones, as they have been used for treating a variety of infections for decades. This familiarity can lead to their continued use in UTI treatment.
Regional Insights
The North America region dominates the Global Urinary Tract Infection Therapeutics Market in 2022. The region boasts well-developed healthcare infrastructure, including hospitals, clinics, research institutions, and pharmaceutical companies. This infrastructure facilitates the research, development, and distribution of UTI therapeutics. North America is home to several major pharmaceutical companies and biotechnology firms that invest heavily in research and development. This industry's innovation contributes to the availability of effective UTI therapeutics. The United States and Canada have a strong research culture, with numerous clinical trials and research studies conducted to improve medical treatments. This environment can lead to the discovery of new and improved UTI therapeutics.
Key Market Players
AstraZeneca PLC.
Bayer AG
Cipla Inc.
GlaxoSmithKline PLC
Shionogi & Co. Ltd
Novartis AG
Pfizer Inc.
Merck & Co. Inc
Bristol-Myers Squibb Company
Almirall SA
Allergan Inc.
Report Scope:
In this report, the Global Urinary Tract Infection Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Urinary Tract Infection Therapeutics Market.
Available Customizations:
Global Urinary Tract Infection Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers:
1. **Advancements in Diagnostics:** Ongoing advancements in diagnostic techniques for urinary tract infections (UTIs) have the potential to enhance patient outcomes by enabling more accurate and timely diagnoses, leading to precise and targeted treatment strategies. Rapid diagnostic tests, designed for point-of-care use, are being developed to provide quick results, empowering healthcare providers to make treatment decisions without waiting for laboratory results. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification assays can identify the genetic material of bacteria causing the infection, offering high sensitivity and specificity. Researchers are also exploring specific biomarkers present in urine or blood to differentiate between bacterial and non-bacterial causes of symptoms, aiding in treatment decisions. The development of smartphone apps and devices with integrated diagnostic capabilities allows users to perform simple urine tests at home and receive immediate results. Microfluidic platforms are being designed to automate and miniaturize diagnostic processes, enabling efficient analysis of urine samples for bacterial presence and biomarkers. Mass spectrometry-based techniques are being employed to identify bacterial pathogens and detect antimicrobial resistance, offering comprehensive insights into the infecting organisms. Advanced culture techniques, including automated systems, expedite the identification of bacterial species causing UTIs and provide information about antibiotic susceptibility. Imaging methods like ultrasound and computed tomography (CT) scans help visualize the urinary tract and identify structural abnormalities that may contribute to recurrent UTIs. Endoscopic procedures allow the direct visualization of the urinary tract, aiding in the identification of anatomical abnormalities, stones, or other factors influencing UTIs. Artificial intelligence (AI) and machine learning algorithms are applied to analyze extensive datasets, identifying patterns and predicting UTI outcomes based on patient history, symptoms, and test results. Metabolomics involves analyzing urine metabolites to gain insights into host-microbe interactions during UTIs, potentially leading to new diagnostic markers. Non-invasive methods for UTI diagnosis, such as urine odor analysis and sensor-based technologies for bacterial detection, are also under exploration. These advancements are expected to drive the growth of the Global Urinary Tract Infection Therapeutics Market.
2. **Growing Aging Population:** The aging population is more vulnerable to infections, including UTIs, due to a decline in immune system function. This vulnerability leads to a higher incidence of infections and a greater demand for appropriate treatment. Older adults often have underlying health conditions like diabetes, kidney disease, and urinary incontinence, which can increase the risk of UTIs and necessitate specialized therapeutics. Anatomical changes in the urinary tract, such as weakened bladder muscles and reduced bladder capacity, contribute to UTIs in older individuals, requiring tailored treatment approaches. The use of urinary catheters, common in older adults, raises the risk of catheter-associated UTIs, making effective therapeutics essential for their management. Additionally, older adults may be more prone to UTIs during hospital stays or in long-term care settings. Effective treatments are crucial in preventing complications and improving patient outcomes. The aging population often experiences polypharmacy, the use of multiple medications, which may increase the risk of UTIs or interact with antibiotics, necessitating careful consideration of therapeutics. Effective therapeutics play a vital role in preventing recurrent infections and associated complications. UTIs can significantly impact the quality of life for older adults, leading to discomfort, pain, and functional limitations. Access to effective therapeutics is essential to alleviate symptoms and enhance well-being. The aging population tends to have higher healthcare utilization rates, including diagnosis, treatment, and management of UTIs, contributing to the demand for UTI therapeutics. As people live longer, they have a higher cumulative risk of experiencing UTIs over their lifetimes. The sustained demand for UTI therapeutics is driven by the ongoing healthcare needs of the aging population, thereby accelerating the demand for the Global Urinary Tract Infection Therapeutics Market.
3. **Increasing Antibiotic Resistance Concerns:** Antibiotic resistance is a growing concern in healthcare as bacteria evolve to resist the effects of antibiotics, diminishing the effectiveness of traditional treatments. With rising antibiotic resistance, the range of antibiotics available for treating UTIs narrows, underscoring the need for novel therapeutic options. UTIs caused by antibiotic-resistant bacteria pose challenges as they are harder to treat with conventional antibiotics, leading to treatment failures, prolonged infections, and a heightened risk of complications. Additionally, antibiotic-resistant UTIs are more likely to recur, as bacteria surviving antibiotic treatment can result in relapses. Effective UTI therapeutics are essential for preventing recurrent infections and halting the cycle of resistance. In healthcare settings, patients with antibiotic-resistant UTIs may experience extended hospital stays, increased healthcare costs, and a higher risk of adverse outcomes. Effective therapeutics are crucial for managing and preventing these infections. The spread of resistant bacteria within communities amplifies the risk of acquiring antibiotic-resistant UTIs, emphasizing the urgency of developing and using effective therapies to mitigate proliferation. Antibiotic resistance is a global public health concern, and infections that were once easily treatable may become life-threatening due to the lack of effective antibiotics. The escalating healthcare costs associated with treating antibiotic-resistant infections, including UTIs, strain healthcare systems and burden both patients and societies. Effective therapeutics can help alleviate these economic challenges. Governments, healthcare organizations, and international bodies are actively addressing antibiotic resistance through awareness campaigns, surveillance programs, and research efforts, emphasizing the importance of developing effective UTI therapeutics. The urgency surrounding antibiotic resistance has spurred research into new drug classes, alternative treatments, and combination therapies. Pharmaceutical companies are investing in the development of innovative therapeutics to combat resistant UTIs. Healthcare providers are increasingly practicing antibiotic stewardship to promote responsible antibiotic use. Developing effective UTI therapeutics that are less likely to contribute to resistance aligns with these stewardship principles. The complexity of antibiotic resistance patterns necessitates personalized treatment strategies, addressing specific bacterial strains and resistance mechanisms. These factors are expected to expedite the demand for the Global Urinary Tract Infection Therapeutics Market.
Key Market Challenges
Emergence of Virulent Strains
Virulent strains of bacteria can exhibit higher levels of resistance to antibiotics, rendering conventional treatments less effective. This can lead to prolonged infections, increased healthcare utilization, and a higher risk of complications. Virulent strains often cause more severe infections with more pronounced symptoms. Patients infected with such strains may experience more discomfort and require more aggressive treatment strategies. UTIs caused by virulent strains can be associated with a higher risk of complications, including kidney infections (pyelonephritis) and bloodstream infections (bacteremia), which can be life-threatening if not promptly treated. Hospitals and healthcare settings can be reservoirs for virulent bacterial strains. UTIs acquired in healthcare settings often involve more resistant and virulent strains, necessitating specialized therapeutics and infection control measures. The emergence of drug-resistant and virulent strains can limit the available treatment options for UTIs. Healthcare providers may need to rely on more powerful antibiotics, combination therapies, or alternative treatment approaches. Treating infections caused by virulent strains can lead to longer hospital stays, increased healthcare costs, and the need for more intensive interventions. This places a burden on healthcare systems and patients alike. The emergence of new virulent strains underscores the need for ongoing antibiotic development. However, the process of developing and bringing new antibiotics to market can be complex and time-consuming.
Limited New Drug Development
The rise of antibiotic-resistant bacteria is a pressing concern. Limited new drug development contributes to a shortage of effective antibiotics against resistant strains, making it difficult to treat certain UTIs. The absence of new drugs can lead to treatment failures, prolonged infections, and recurrent UTIs. This can result in patient discomfort, increased healthcare utilization, and higher costs. With few new drugs entering the market, healthcare providers may have limited options to choose from. This could lead to over-reliance on a small set of antibiotics, potentially exacerbating resistance issues. The lack of new drug development can lead to economic consequences, including increased healthcare costs due to extended treatment periods and hospitalizations for severe cases. A lack of innovation hinders the discovery of novel treatment approaches, leaving patients with fewer alternatives to traditional antibiotics. The aging population and increased healthcare demand mean that UTI treatment requirements are on the rise. New drugs are crucial to meet this growing demand. Limited potential for profit from developing new UTI drugs might discourage pharmaceutical companies from investing in research and development efforts. UTIs can be caused by various bacterial species. Developing drugs that target a wide range of pathogens requires substantial research and resources.
Key Market Trends
Antibiotic Stewardship
Antibiotic stewardship refers to the coordinated efforts to promote the responsible and judicious use of antibiotics to prevent the development of antibiotic resistance, improve patient outcomes, and optimize healthcare resources. Antibiotic stewardship programs aim to ensure that antibiotics are prescribed only when necessary and appropriate. This approach helps prevent the overuse and misuse of antibiotics, preserving their effectiveness for future use. One of the primary goals of antibiotic stewardship is to combat the development of antibiotic resistance. By limiting unnecessary antibiotic use, the emergence and spread of resistant bacteria can be slowed down. Antibiotic stewardship encourages healthcare providers to explore alternative treatment options, such as non-antibiotic therapies, for managing UTIs when appropriate. Stewardship practices emphasize individualized treatment plans based on the patient's condition, the causative pathogen, and antibiotic susceptibility. This approach improves treatment outcomes and minimizes unnecessary exposure to antibiotics. Antibiotic stewardship programs involve educating healthcare professionals, patients, and the public about the importance of proper antibiotic use, the risks of resistance, and the benefits of responsible prescribing. Stewardship aligns with evidence-based guidelines for UTI treatment, ensuring that antibiotics are prescribed according to established best practices. Electronic health record systems and clinical decision support tools can assist healthcare providers in selecting appropriate antibiotics based on patient-specific factors and local resistance patterns.
Segmental Insights
Indication Insights
In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by complicated UTI segment in the forecast period and is predicted to continue expanding over the coming years. Complicated UTIs are infections that occur in individuals with anatomical or functional abnormalities of the urinary tract, underlying health conditions, or compromised immune systems. These infections tend to be more severe and challenging to treat. Therefore, healthcare providers may rely on more potent or specialized therapies, contributing to the dominance of this segment. The complexity of complicated UTIs might necessitate the use of specialized or combination therapies to effectively treat the infection. This requirement for tailored treatments could result in a higher demand for specific therapeutic options. As the population ages and chronic health conditions become more prevalent, the incidence of complicated UTIs could increase. This demographic shift might contribute to the dominance of this segment.
Drug Insights
In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by quinolones drugs segment and is predicted to continue expanding over the coming years. Quinolones are broad-spectrum antibiotics, which means they are effective against a wide range of bacteria. UTIs can be caused by various bacterial strains, and quinolones' ability to target a broad spectrum of bacteria makes them versatile in treating different types of UTIs. Many quinolone antibiotics can be administered orally, making them convenient for both healthcare providers and patients. This ease of administration can contribute to their popularity in the treatment of UTIs. Quinolones often have a relatively fast onset of action, leading to quick symptom relief for patients suffering from UTIs. Healthcare providers often have experience with prescribing quinolones, as they have been used for treating a variety of infections for decades. This familiarity can lead to their continued use in UTI treatment.
Regional Insights
The North America region dominates the Global Urinary Tract Infection Therapeutics Market in 2022. The region boasts well-developed healthcare infrastructure, including hospitals, clinics, research institutions, and pharmaceutical companies. This infrastructure facilitates the research, development, and distribution of UTI therapeutics. North America is home to several major pharmaceutical companies and biotechnology firms that invest heavily in research and development. This industry's innovation contributes to the availability of effective UTI therapeutics. The United States and Canada have a strong research culture, with numerous clinical trials and research studies conducted to improve medical treatments. This environment can lead to the discovery of new and improved UTI therapeutics.
Key Market Players
AstraZeneca PLC.
Bayer AG
Cipla Inc.
GlaxoSmithKline PLC
Shionogi & Co. Ltd
Novartis AG
Pfizer Inc.
Merck & Co. Inc
Bristol-Myers Squibb Company
Almirall SA
Allergan Inc.
Report Scope:
In this report, the Global Urinary Tract Infection Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Urinary Tract Infection Therapeutics Market, By Drug:
- Penicillin and Combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitrofurans
- Other Drugs
- Urinary Tract Infection Therapeutics Market, By Indication:
- Complicated UTI
- Uncomplicated UTI
- Other Indications
- Global Urinary Tract Infection Therapeutics Market, By region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Urinary Tract Infection Therapeutics Market.
Available Customizations:
Global Urinary Tract Infection Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. IMPACT OF COVID-19 ON GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs)
6.2.2. By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications)
6.2.3. By Region
6.2.4. By Company (2022)
6.3. Market Map
7. ASIA PACIFIC URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug
7.2.2. By Indication
7.2.3. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Urinary Tract Infection Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug
7.3.1.2.2. By Indication
7.3.2. India Urinary Tract Infection Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug
7.3.2.2.2. By Indication
7.3.3. Australia Urinary Tract Infection Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug
7.3.3.2.2. By Indication
7.3.4. Japan Urinary Tract Infection Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug
7.3.4.2.2. By Indication
7.3.5. South Korea Urinary Tract Infection Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug
7.3.5.2.2. By Indication
8. EUROPE URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug
8.2.2. By Indication
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France Urinary Tract Infection Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug
8.3.1.2.2. By Indication
8.3.2. Germany Urinary Tract Infection Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug
8.3.2.2.2. By Indication
8.3.3. Spain Urinary Tract Infection Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug
8.3.3.2.2. By Indication
8.3.4. Italy Urinary Tract Infection Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug
8.3.4.2.2. By Indication
8.3.5. United Kingdom Urinary Tract Infection Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug
8.3.5.2.2. By Indication
9. NORTH AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug
9.2.2. By Indication
9.2.3. By Country
9.3. North America: Country Analysis
9.3.1. United States Urinary Tract Infection Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug
9.3.1.2.2. By Indication
9.3.2. Mexico Urinary Tract Infection Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug
9.3.2.2.2. By Indication
9.3.3. Canada Urinary Tract Infection Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug
9.3.3.2.2. By Indication
10. SOUTH AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug
10.2.2. By Indication
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Urinary Tract Infection Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug
10.3.1.2.2. By Indication
10.3.2. Argentina Urinary Tract Infection Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug
10.3.2.2.2. By Indication
10.3.3. Colombia Urinary Tract Infection Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug
10.3.3.2.2. By Indication
11. MIDDLE EAST AND AFRICA URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug
11.2.2. By Indication
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Urinary Tract Infection Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug
11.3.1.2.2. By Indication
11.3.2. Saudi Arabia Urinary Tract Infection Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug
11.3.2.2.2. By Indication
11.3.3. UAE Urinary Tract Infection Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug
11.3.3.2.2. By Indication
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE ANALYSIS
17. COMPETITIVE LANDSCAPE
17.1. Business Overview
17.2. Company Snapshot
17.3. Products & Services
17.4. Financials (In case of listed companies)
17.5. Recent Developments
17.6. SWOT Analysis
17.6.1. AstraZeneca PLC.
17.6.2. Bayer AG
17.6.3. Cipla Inc.
17.6.4. GlaxoSmithKline PLC
17.6.5. Shionogi & Co. Ltd
17.6.6. Novartis AG
17.6.7. Pfizer Inc.
17.6.8. Merck & Co. Inc
17.6.9. Bristol-Myers Squibb Company
17.6.10. Almirall SA
17.6.11. Allergan Inc.
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. IMPACT OF COVID-19 ON GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs)
6.2.2. By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications)
6.2.3. By Region
6.2.4. By Company (2022)
6.3. Market Map
7. ASIA PACIFIC URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug
7.2.2. By Indication
7.2.3. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Urinary Tract Infection Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug
7.3.1.2.2. By Indication
7.3.2. India Urinary Tract Infection Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug
7.3.2.2.2. By Indication
7.3.3. Australia Urinary Tract Infection Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug
7.3.3.2.2. By Indication
7.3.4. Japan Urinary Tract Infection Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug
7.3.4.2.2. By Indication
7.3.5. South Korea Urinary Tract Infection Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug
7.3.5.2.2. By Indication
8. EUROPE URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug
8.2.2. By Indication
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France Urinary Tract Infection Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug
8.3.1.2.2. By Indication
8.3.2. Germany Urinary Tract Infection Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug
8.3.2.2.2. By Indication
8.3.3. Spain Urinary Tract Infection Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug
8.3.3.2.2. By Indication
8.3.4. Italy Urinary Tract Infection Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug
8.3.4.2.2. By Indication
8.3.5. United Kingdom Urinary Tract Infection Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug
8.3.5.2.2. By Indication
9. NORTH AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug
9.2.2. By Indication
9.2.3. By Country
9.3. North America: Country Analysis
9.3.1. United States Urinary Tract Infection Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug
9.3.1.2.2. By Indication
9.3.2. Mexico Urinary Tract Infection Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug
9.3.2.2.2. By Indication
9.3.3. Canada Urinary Tract Infection Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug
9.3.3.2.2. By Indication
10. SOUTH AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug
10.2.2. By Indication
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Urinary Tract Infection Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug
10.3.1.2.2. By Indication
10.3.2. Argentina Urinary Tract Infection Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug
10.3.2.2.2. By Indication
10.3.3. Colombia Urinary Tract Infection Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug
10.3.3.2.2. By Indication
11. MIDDLE EAST AND AFRICA URINARY TRACT INFECTION THERAPEUTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug
11.2.2. By Indication
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Urinary Tract Infection Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug
11.3.1.2.2. By Indication
11.3.2. Saudi Arabia Urinary Tract Infection Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug
11.3.2.2.2. By Indication
11.3.3. UAE Urinary Tract Infection Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug
11.3.3.2.2. By Indication
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE ANALYSIS
17. COMPETITIVE LANDSCAPE
17.1. Business Overview
17.2. Company Snapshot
17.3. Products & Services
17.4. Financials (In case of listed companies)
17.5. Recent Developments
17.6. SWOT Analysis
17.6.1. AstraZeneca PLC.
17.6.2. Bayer AG
17.6.3. Cipla Inc.
17.6.4. GlaxoSmithKline PLC
17.6.5. Shionogi & Co. Ltd
17.6.6. Novartis AG
17.6.7. Pfizer Inc.
17.6.8. Merck & Co. Inc
17.6.9. Bristol-Myers Squibb Company
17.6.10. Almirall SA
17.6.11. Allergan Inc.
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
